Mitchell Kronenberg

Mitchell Kronenberg received a B.A. from Columbia University, a Ph.D. from the California Institute of Technology, and served on the faculty of the UCLA School of Medicine from 1986-1997. He joined the La Jolla Institute for Immunology in 1997 and has been the President there since 2003. The Institute has grown in accomplishment and reputation under his leadership.

Dr. Kronenberg’s research interests include natural killer T cells, other innate lymphocytes such as MAIT cells and ILC, regulation of mucosal immunology and the microbiome, and pathogenesis of inflammatory bowel disease. He has co-authored more than 350 publications, and is a fellow of the American Association for the Advancement of Science (AAAS), a Distinguished Fellow of the American Association of Immunologists, recipient of an NIH MERIT award, and is an Institute for Scientific Information (ISI) Highly Cited Scientist. In 2016, he was named the most admired CEO (large nonprofit organization category) by the San Diego Business Journal. He is an advisor to a number of organizations including serving as a member of the Board of Scientific Counselors for Basic Science, National Cancer Institute and he has been involved with Invivoscribe since its founding.